非阿司匹林类NSAIDs与结肠镜后结直肠癌风险降低相关
结果显示,NSAIDs使用与3年内PCCRC风险降低相关(aHR 0.54,95%CI 0.41-0.70),而阿司匹林无此关联(aHR 1.01,95%CI 0.80-1.28)。
要点
- 非阿司匹林类NSAIDs使用与3年内PCCRC风险降低相关(aHR 0.54)。
- 阿司匹林使用与PCCRC风险无显著关联(aHR 1.01)。
- NSAIDs对近端和远端癌均显示保护关联,且存在疗程-频率反应关系。
核心结论
- 非阿司匹林类NSAIDs与基线结肠镜阴性后3年内PCCRC风险降低相关,而阿司匹林无此关联。
研究设计与样本
- 排除索引结肠镜6个月内检出CRC、既往CRC、炎症性肠病及既往结肠切除术者。
- 主要结局为索引结肠镜后6至36个月诊断的PCCRC-3y。
- NSAIDs和阿司匹林使用定义为索引结肠镜前5年内累计使用≥90天。
- 采用倾向评分回归调整22项协变量(包括患者因素、合并用药及内镜中心表现)计算调整风险比(aHR)。
主要发现
- NSAIDs使用与PCCRC-3y风险降低相关(aHR 0.54,95%CI 0.41-0.70),但与3年后发生的CRC无显著关联(aHR 0.78,95%CI 0.56-1.09)。
- NSAIDs对近端癌的aHR为0.48(95%CI 0.24-0.95),对远端癌的aHR为0.55(95%CI 0.40-0.74)。
- 观察到疗程和频率反应关系(Ptrend < 0.001)。
- 阿司匹林使用的aHR为1.01(95%CI 0.80-1.28)。
临床怎么用
- 对于基线结肠镜阴性患者,非阿司匹林类NSAIDs使用史可能与较低的3年内PCCRC风险相关,但需结合个体情况评估。
- 阿司匹林使用未显示与PCCRC风险降低相关,不应以此作为PCCRC预防依据。
- NSAIDs对近端和远端癌的关联均存在,且存在剂量-反应关系,提示需关注用药疗程和频率。
局限性
- 回顾性队列设计可能存在残余混杂。
- NSAIDs和阿司匹林暴露基于数据库定义,可能存在错分。
- 研究人群为香港地区人群,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although nonsteroidal anti-inflammatory drugs (NSAIDs) reduce colorectal cancer (CRC) risk, their role in preventing post-colonoscopy CRC (PCCRC) remains undetermined. AIMS: To investigate whether NSAIDs reduce PCCRC risk after a negative baseline colonoscopy METHODS: This is a retrospective cohort study based on a territory-wide healthcare database of Hong Kong. All patients (aged 40 or above) who underwent colonoscopies between 2005 and 2013 were identified. Exclusion criteria included CRC detected within 6 months of index colonoscopy, prior CRC, inflammatory bowel disease and prior colectomy. The primary outcome was PCCRC-3y diagnosed between 6 and 36 months after index colonoscopy. Sites of CRC were categorised as proximal (proximal to splenic flexure) and distal. The adjusted hazards ratio (aHR) of PCCRC-3y with NSAID and aspirin use (defined as cumulative use for ≥90 days within 5 years before index colonoscopy) was derived by propensity score (PS) regression adjustment of 22 covariates (including patient factors, concurrent medication use and endoscopy centre's performance). RESULTS: Of 187 897 eligible patients, 21 757 (11.6%) were NSAID users. 854 (0.45%) developed PCCRC-3y (proximal cancer: 147 [17.2%]). NSAIDs were associated with a lower PCCRC-3y risk (aHR: 0.54, 95% CI: 0.41-0.70), but not CRC that developed >3 years (aHR: 0.78, 95% CI 0.56-1.09). The aHR was 0.48 (95% CI: 0.24-0.95) for proximal and 0.55 (95% CI: 0.40-0.74) for distal cancer. A duration- and frequency response relationship was observed (Ptrend < 0.001). For aspirin, the aHR was 1.01 (95% CI: 0.80-1.28). CONCLUSIONS: Non-aspirin NSAIDs were associated with lower PCCRC risk after a negative baseline colonoscopy.
引用
- Cheung KS, Chen L, Chan EW, et al. Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer. Aliment Pharmacol Ther. 2020. PMID: 32201976. doi:10.1111/apt.15693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。